The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Open accessAbstract
Modern vaccines have largely shifted from using whole, killed or attenuated pathogens to being based on subunit components. Since this diminishes immunogenicity, vaccine adjuvants that enhance the immune response to purified antigens are critically needed. Further advantages of adjuvants include dose sparing, increased vaccine efficacy in immunocompromised individuals and the potential to protect against highly variable pathogens by broadening the immune response. Due to their ability to link the innate with the adaptive immune response, Toll-like receptor (TLR) agonists are highly promising as adjuvants in vaccines against life-threatening and complex diseases such as cancer, AIDS and malaria. TLRs are transmembrane receptors, which are predominantly expressed by innate immune cells. They can be classified into cell surface (TLR1, TLR2, TLR4, TLR5, TLR6) and intracellular TLRs (TLR3, TLR7, TLR8, TLR9), expressed on endosomal membranes. Besides a transmembrane domain, each TLR possesses a leucine-rich repeat (LRR) segment that mediates PAMP/DAMP recognition and a TIR domain that delivers the downstream signal transduction and initiates an inflammatory response. Thus, TLRs are excellent targets for adjuvants to provide a “danger” signal to induce an effective immune response that leads to long-lasting protection. The present review will elaborate on applications of TLR ligands as vaccine adjuvants and immunotherapeutic agents, with a focus on clinically relevant adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 5×
“MGN1703 is a novel, synthetic, covalently closed DNA molecule, which activates the TLR9 signalling pathway.”
BackgroundInfluentialmRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 2×
“The immunostimulatory feature of mRNA vaccines may provide an adjuvant activity to drive DC maturation, thus inducing resilient T and B cell responses [80].”
BackgroundHoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., & Akira, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3749 · Cited by 3,374
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
The history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714021 · Cited by 652
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines
Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., Takeshita, F., Coban, C., et al. (2008) · Nature · doi:10.1038/nature06537 · Cited by 628
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, S., Liu, M., Davis, H. L., et al. (2004) · European Journal of Immunology · doi:10.1002/eji.200324032 · Cited by 595
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies
Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., & de Bernard, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055375 · Cited by 585
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Stanley, M. A. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01151.x · Cited by 377
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 337
TLR signalling and activation of IRFs: revisiting old friends from the NF-κB pathway
Moynagh, P. N. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.06.009 · Cited by 336
Scheiermann, J., & Klinman, D. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.065 · Cited by 322
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287
TLR8: the forgotten relative revindicated
Cervantes, J. L., Weinerman, B., Basole, C., & Salazar, J. C. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.38 · Cited by 274
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Dowling, J. K., & Mansell, A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.22 · Cited by 273
Sabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A. A., Ritter, G., Aghajanian, C., Bell-McGuinn, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2189 · Cited by 272
Dubensky, T. W., & Reed, S. G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.007 · Cited by 259
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Vasilakos, J. P., & Tomai, M. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811208 · Cited by 254
Janeway, C. A. (2013) · PubMed · Cited by 253
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Wang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Vaccine adjuvant uses of poly-IC and derivatives
Martins, K. A., Bavari, S., & Salazar, A. M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.966085 · Cited by 220
Dzamko, N., Inesta-Vaquera, F., Zhang, J., Xie, C., Cai, H., Arthur, S., Tan, L., Choi, H., Gray, N., Cohen, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039132 · Cited by 213
Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease
Zhao, G.-N., Jiang, D.-S., & Li, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.030 · Cited by 212
Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides
Mutwiri, G. K., Nichani, A. K., Babiuk, S., & Babiuk, L. A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.022 · Cited by 208
Luabeya, A. K. K., Kagina, B. M. N., Tameris, M. D., Geldenhuys, H., Hoff, S. T., Shi, Z., Kromann, I., Hatherill, M., Mahomed, H., Hanekom, W. A., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.051 · Cited by 198
New hepatitis B vaccine formulated with an improved adjuvant system
Kundi, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.133 · Cited by 193
Cooper, C. L., Davis, H. L., Angel, J. B., Morris, M. L., Elfer, S. M., Seguin, I., Krieg, A. M., & Cameron, D. W. (2005) · AIDS · doi:10.1097/01.aids.0000183514.37513.d2 · Cited by 191
Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189
Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186
Lamm, D. L., Riggs, D. R., Traynelis, C. L., & Nseyo, U. O. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67427-5 · Cited by 186
Frank, M. J., Reagan, P. M., Bartlett, N. L., Gordon, L. I., Friedberg, J. W., Czerwinski, D. K., Long, S. R., Hoppe, R. T., Janssen, R., Candia, A. F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0743 · Cited by 186
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Li, K., Qu, S., Chen, X., Wu, Q., & Shi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020404 · Cited by 180
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164
Coler, R. N., Day, T. A., Ellis, R., Piazza, F. M., Beckmann, A. M., Vergara, J., Rolf, T., Lu, L., Alter, G., Hokey, D., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0057-5 · Cited by 164
IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
Schellack, C., Prinz, K., Egyed, A., Fritz, J. H., Wittmann, B., Ginzler, M., Swatosch, G., Zauner, W., Kast, C., Akira, S., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.071 · Cited by 158
Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Coler, R. N., Baldwin, S. L., Shaverdian, N., Bertholet, S., Reed, J., Raman, V. S., Lu, X., DeVos, J. R., Hancock, K., Katz, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013677 · Cited by 150
Bhatia, S., Miller, N. J., Lu, H., Longino, N. V., Ibrani, D., Shinohara, M. M., Byrd, D. R., Parvathaneni, U., Kulikauskas, R. M., ter Meulen, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0469 · Cited by 146
Smith, M. E. B., Haney, E., McDonagh, M., Pappas, M., Daeges, M., Wasson, N., Fu, R., & Nelson, H. D. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0114 · Cited by 142 · cited 5×
“In patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), treatment with the poly-IC12U drug rintatolimod led to an improvement in exercise tolerance and showed dose-sparing effects in a Phase III clinical trial in 2012 [23].”
BackgroundInfluentialTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1088631 · Cited by 142
Pollinex Quattro: An innovative four injections immunotherapy In allergic rhinitis
Rosewich, M., Lee, D. T., & Zielen, S. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24631 · Cited by 141
Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer
Jasani, B., Navabi, H., & Adams, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.071 · Cited by 141
Salazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Heineman, T. C., Cunningham, A. L., & Levin, M. J. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.009 · Cited by 127
Sabado, R. L., Pavlick, A. C., Gnjatic, S., Cruz, C. M., Vengco, I., Hasan, F., Spadaccia, M. R., Darvishian, F., Chiriboga, L. A., Holman, R. M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0202 · Cited by 100
Schmoll, H., Wittig, B., Arnold, D., Riera‐Knorrenschild, J., Nitsche, D., Kroening, H., Mayer, F., Andel, J., Ziebermayr, R., & Scheithauer, W. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1682-7 · Cited by 97
Agarwala, S. S., Neuberg, D. S., Park, Y., & Kirkwood, J. M. (2004) · Cancer · doi:10.1002/cncr.20166 · Cited by 94
Thompson, K. A., Strayer, D. R., Salvato, P. D., Thompson, C. E., Klimas, N., Molavi, A., Hamill, A. K., Zheng, Z., Ventura, D., & Carter, W. A. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01709367 · Cited by 92
Pillet, S., Aubin, É., Trépanier, S., Poulin, J., Yassine‐Diab, B., ter Meulen, J., Ward, B. J., & Landry, N. (2018) · npj Vaccines · doi:10.1038/s41541-017-0043-3 · Cited by 87
Strayer, D. R., Carter, W. A., Stouch, B. C., Stevens, S. R., Bateman, L., Cimoch, P. J., Lapp, C. W., Peterson, D. L., the Chronic Fatigue Syndrome AMP-516 Study Group, & Mitchell, W. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031334 · Cited by 84
Harrison, L., Skinner, S. L., Marbury, T., et al. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0465-4 · Cited by 78
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
Wittig, B., Schmidt, M., Scheithauer, W., & Schmoll, H. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.002 · Cited by 78
Toll-like receptors in Alzheimer's disease
Momtazmanesh, S., Perry, G. L., & Rezaei, N. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577362 · Cited by 76
Krone, B., Kölmel, K. F., Grange, J. M., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00625-7 · Cited by 75
van den Ende, C., Marano, C., van Ahee, A., Bunge, E. M., & Moerlooze, L. D. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1338568 · Cited by 68
Hesse, E. M., Shimabukuro, T. T., Su, J. R., Hibbs, B. F., Dooling, K. L., Goud, R., Lewis, P., Ng, C. S., & Cano, M. V. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6804a4 · Cited by 63
Pollinex®Quattro: a novel and well–tolerated, ultra short–course allergy vaccine
Patel, P. M., & Salapatek, A. M. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.5.617 · Cited by 62
Toll-like receptors in mediating pathogenesis in systemic sclerosis
Frasca, L., & Lande, R. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13426 · Cited by 59
Ellis, R. D., Wu, Y., Martin, L. B., Shaffer, D., Miura, K., Aebig, J. A., Orcutt, A. C., Rausch, K. M., Zhu, D., Mogensen, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046094 · Cited by 57
Entolimod as a radiation countermeasure for acute radiation syndrome
Singh, V. K., & Seed, T. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.003 · Cited by 56
Identification of Aim2 as a Sensor for DNA Vaccines
Suschak, J. J., Wang, S., Fitzgerald, K. A., & Lu, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402530 · Cited by 55
TLR Agonists as Adjuvants for Cancer Vaccines
Li, J., Balic, J. J., Yu, L., & Jenkins, B. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5987-2_9 · Cited by 47
Mett, V. L., Komarova, E. A., Greene, K. M., Bespalov, I. A., Brackett, C. M., Gillard, B. M., Gleiberman, A. S., Toshkov, I., Aygun‐Sunar, S., Johnson, C., et al. (2017) · Oncogene · doi:10.1038/onc.2017.346 · Cited by 47
Messenger RNA vaccines against SARS-CoV-2
Topol, E. J. (2021) · Cell · doi:10.1016/j.cell.2020.12.039 · Cited by 42
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
Krarup, A. R., Abdel‐Mohsen, M., Schleimann, M. H., Vibholm, L. K., Engen, P. A., Dige, A. K., Wittig, B., Schmidt, M., Green, S. J., Naqib, A. D., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.59 · Cited by 40
TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
Schleimann, M. H., Kobberø, M.-L., Vibholm, L. K., Kjær, K., Giron, L. B., Busman‐Sahay, K., Chan, C. N., Nekorchuk, M. D., Schmidt, M., Wittig, B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.005 · Cited by 39
Ezoe, S., Palacpac, N., Tetsutani, K., Yamamoto, K., Okada, K., Taira, M., Nishida, S., Hirata, H., Ogata, A., Yamada, T., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.056 · Cited by 29
HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population
Fabrizi, F., Cerutti, R., Nardelli, L., Tripodi, F., & Messa, P. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.06.010 · Cited by 22
Somaiah, N., Chawla, S. P., Block, M. S., Morris, J. C., Do, K. T., Kim, J. W., Druta, M., Sankhala, K. K., Hwu, P., Gnjatic, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11006 · Cited by 21
Haskins‐Coulter, T., Southern, J., Andrews, N. J., & Miller, E. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1277846 · Cited by 18
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Recent Advances in Studying Toll-like Receptors with the Use of Computational Methods
Bzówka, M., Bagrowska, W., & Góra, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00419 · Cited by 34
Honorato, L., Bonilla, J. J. A., Valdez, A. F., Frases, S., Araújo, G. R. D. S., Sabino, A. L. R. D. N., da Silva, N. M., Ribeiro, L., Ferreira, M. D. S., Kornetz, J., et al. (2024) · mSphere · doi:10.1128/msphere.00467-24 · Cited by 28
Metadata
- Authors
- Luchner, M., Reinke, S., & Milicic, A.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-01-22
- Volume
- 13
- Issue
- 2
- Pages
- 142
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3122174179
- Cited by
- 285
- References
- 88
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.